Related Experiment Videos
Peptide-derived protease-activated receptor-1 (PAR-1) antagonists
Steven M Seiler1, Michael S Bernatowicz
1Department of Vascular Biology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08534, USA. steven.seiler@bms.com
Current Medicinal Chemistry. Cardiovascular and Hematological Agents
|August 20, 2004
Summary
Protease activated receptor-1 (PAR-1) antagonists were developed through peptide modification. These PAR-1 antagonists are valuable tools for studying receptor signaling in various cell types.
Area of Science:
- Biochemistry
- Pharmacology
- Molecular Biology
Background:
- Protease activated receptor-1 (PAR-1) is a G-protein coupled receptor activated by proteolytic cleavage, exposing a tethered ligand.
- Peptide agonists mimicking the tethered ligand activate PAR-1, and their structure-activity relationships have been extensively studied.
Purpose of the Study:
- To develop rationally designed peptide antagonists for PAR-1.
- To utilize these antagonists in pharmacological studies to elucidate PAR-1 signaling roles.
Main Methods:
- Modification of activating peptides to create antagonists.
- Radiolabeling of high-affinity peptide agonists and antagonists for binding assays.
- Screening of libraries using radioligands to identify non-peptide antagonists.
Main Results:
- Potent PAR-1 peptide antagonists were designed via N-terminal and 3-position modifications.
- Peptide antagonists aided in resolving PAR-1 signaling contributions in platelets and endothelial cells.
- Radioligands facilitated the identification of diverse non-peptide PAR-1 antagonist chemotypes.
Conclusions:
- Peptide-based PAR-1 agonists and antagonists are crucial tools for understanding receptor function.
- The development of PAR-1 antagonists has significantly advanced research into its physiological and pathological roles.
- PAR-1 remains a significant drug target with ongoing discovery of novel antagonists.